KARACİĞER SİROZLU HASTALARDA SERUM NESFATİN-1 DÜZEYLERİNİN HASTALIK ŞİDDETİ VE KOMPLİKASYONLARI İLE İLİŞKİSİ

Year 2024, Volume: 87 Issue: 3, 209 - 214, 19.07.2024

Özlem Kandemir Alibakan , Hasan Eruzun , İlkim Deniz Toprak , Uğur Yılmaz , Mehmet Alptekin Acar , İpek Bilge Aslan , Merve Polat Onmaz , Yasemin Gökden , Yücel Arman , Tufan Tükek

https://doi.org/10.26650/IUITFD.1365883

Abstract

Amaç: Nesfatin-1, iştahın ve enerji alımının düzenlenmesinde önemli rolleri olan anorektik bir polipeptittir. Kaşeksi ve malnut risyon sirozlu bireylerde yaygındır. Nesfatin-1 düzeylerinin siroz lu hastalardaki artışının sirozdaki katabolik süreçle alakalı olabi leceği hipoteziyle nesfatin-1 serum düzeyleri ve siroz aşamaları ilişkisini inceledik.
Gereç ve Yöntem: Çalışmamıza 51 sirozlu hasta ve 30 sağlıklı gönüllü alındı. Serum örneklerinden nesfatin-1 düzeyleri ELISA kullanılarak karşılaştırıldı. Sirozlu hastaların Child-Pugh evreleri ve multifaktöriyel son dönem karaciğer hastalığı modeli (MELD) skorları hesaplanarak nesfatin-1 ile ilişkileri incelendi. Ek olarak siroz komplikasyonları ile nesfatin-1 arasındaki ilişki araştırıldı.
Bulgular: Nesfatin-1 düzeyleri sirozlu hasta grubunda kontrol grubuna göre anlamlı olarak yüksek bulundu (p=0,001). Hasta grubu kompanse ve dekompanse olarak ayrılıp, kontrol grubu ile karşılaştırıldı. Kompanse siroz grubunda nesfatin-1 düzeyleri an lamlı olarak yüksek bulundu (p=0,01). Sirozlu hastalar Child-Pugh evrelerine ve MELD skorlarına göre sınıflandırıldığında bu gru plar ile nesfatin-1 düzeyleri arasında anlamlı bir ilişki saptanmadı.
Sonuç: Sirozlu hastalarda kompanze halin sürdürülmesinde nes fatin-1’in antioksidan, antiinflamatuar ve antiapoptotik etkileri olabilir. Dekompanse sirozda nesfatin-1 düzeylerinin düşük olması savunma mekanizması ve yetersiz üretimden kaynaklanabilir.

Keywords

Nesfatin-1, karaciğer, siroz, dekompansas yon, antienflamatuvar, antioksidan

THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS

Abstract

Objective: Nesfatin-1 is an anorectic polypeptide that plays im portant roles in regulating appetite and energy intake. Cachexia and malnutrition are common in individuals with cirrhosis. We ex amined the relationship between serum nesfatin-1 levels and stage of cirrhosis, with the hypothesis that an increase in nesfatin-1 levels in patients with cirrhosis may be related to this catabolic process.
Material and Method: The study includes 51 patients with cirrhosis and 30 healthy volunteers. Nesfatin-1 levels in serum samples were compared using the enzyme-linked immunosorbent assay (ELISA). We calculated the Child-Pugh stages and Model for End-Stage Liver Disease (MELD) scores of patients with cirrhosis and examined their relationship with nesfatin-1. We’ve also investigated the relationship between cirrhosis complications and nesfatin-1.
Results: We found nesfatin-1 levels to be significantly higher in the cirrhosis patient group compared to the control group (p=0.001). The patient group was divided into those with compensated and those with decompensated liver cirrhosis and compared with the control group. Nesfatin-1 levels were found to be significantly higher in the compensated liver cirrhosis group (p=0.01). When classifying the patients with cirrhosis based on their Child-Pugh stages and MELD scores, no significant relationship was detected between these groups and their nesfatin-1 levels.
Conclusion: Nesfatin-1 may have antioxidant, anti-inflammatory, and anti-apoptotic effects in maintaining the state of patients with compensated liver cirrhosis. Low levels of nesfatin-1 in decompensated liver cirrhosis may result from defense mecha nisms and inadequate production.

Keywords

Nesfatin-1, liver, cirrhosis, decompensation, anti-in f lammatory, antioxidant

Ethical Statement

Our study was approved by the University of Health Sciences Türkiye, Prof. Dr. Cemil Taşçıoğlu City Hospital Ethics Committee (Decision Number: 1143).

References

• 1. Moctezuma-Velazquez C, Garcia-Juarez I, Soto-Solis R, Hernandez-Cortes J, Torre A. Nutritional assessment and treatment of patients with liver cirrhosis. Nutrition 2013;29:1279-85. [CrossRef] google scholar
• 2. Traub J, Reiss L, Aliwa B, Stadlbauer V. Malnutrition in patients with liver cirrhosis. Nutrients 2021;13(2):540. [CrossRef] google scholar
• 3. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443(7112):709-12. [CrossRef] google scholar
• 4. Psilopanagioti A, Nikou S, Papadaki H. Nucleobindin-2/ nesfatin-1 in the human hypothalamus is reduced in obese subjects and colocalizes with oxytocin, vasopressin, melanin-concentrating hormone, and cocaine-and amphetamine-regulated transcript. Neuroendocrinol 2019;108(3):190-200. [CrossRef] google scholar
• 5. Prinz P, Stengel A. Nesfatin-1: current status as a peripheral hormone and future prospects. Curr Opin Pharmacol 2016;31:19-24. [CrossRef] google scholar
• 6. Xu Y, Chen F. Antioxidant, anti-inflammatory, and anti-apoptotic activities of nesfatin-1: a review. J Inflamm Res 2020;13:607-17. [CrossRef] google scholar
• 7. Schalla MA, Stengel A. Current understanding of the role of nesfatin-1. J Endocr Soc 2018;2(10):1188-206. [CrossRef] google scholar
• 8. Ogiso K, Asakawa A, Amitani H, Nakahara T, Ushikai M, Haruta I, et al. Plasma nesfatin-1 concentrations in restrictingtype anorexia nervosa. Peptides 2011;32(1):150-3. [CrossRef] google scholar
• 9. Aydin F, Cindoglu C, Kirhan I, Uyanikoglu A, Yenice N. Serum prolidase, urotensin-2, and nesfatin levels in patients with compensated or uncompensated cirrhosis. Ann Med Res 2019;26(8):1666-9 [CrossRef] google scholar
• 10. Di Pascoli M, Sacerdoti D, Pontisso P, Angeli P, Bolognesi M. Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis. J Vasc Res 2017;54(2):92-9. [CrossRef] google scholar
• 11. Frances R, Munoz C, Zapater P, Uceda F, Gascon I, Pascual S, et al. Bacterial DNA activates cell-mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004;53(6):860-4. [CrossRef] google scholar
• 12. Úbeda M, Munoz L, Borrero MJ, Díaz D, Francés R, Monserrat J, et al. Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology 2010;52(6):2086-95. [CrossRef] google scholar
• 13. Özsavci D, Erşahin M, Şener A, Özakpinar ÖB, Toklu HZ, Akakín D, et al. The novel function of nesfatin-1 as an antiinflammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in rats. Neurosurgery 2011;68:1699-708. [CrossRef] google scholar
• 14. Yavuz M, Ozsoy M, Celep B, Gülsari Y, Aslan E, Bozbiyik O, et al. Anti-inflammatory and anti-apoptotic effect of nesfatin-1 on liver ischemia-reperfusion injury. Ann Ital Chir 2020;91:207-14. google scholar
• 15. Thébault E, Purucker M, Whaler KA, Langlais B, Sabaka TJ. The magnetic field of the Earth’s lithosphere. Space Sci Rev 2010;155:95-127. [CrossRef] google scholar
• 16. Kolgazi M, Ozdemir-Kumral Z, Cantali-Ozturk C, Demirci E, Yuksel M, Sirvanci S, et al. Anti-inflammatory effects of nesfatin-1 on acetic acid-induced gastric ulcer in rats: involvement of cyclo-oxygenase pathway. J Physiol Pharmacol 2017;68(5):765-77. google scholar
• 17. Toprak İ, Eruzun H, Kutlu Y, Arman Y, Yumuştutan P, Yoldemir Aydın Ş, et al. Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock. J Exp Clin Med 2022;39(1):1-6. [CrossRef] google scholar
• 18. Wernecke K, Lamprecht I, Jöhren O, Lehnert H, Schulz C. Nesfatin-1 increases energy expenditure and reduces food intake in rats. Obesity (Silver Spring) 2014;22(7):1662-8. [CrossRef] google scholar
• 19. Yosten GL, Samson WK. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am Physiol-Regul Integr Comp Physiol 2010;298(6):R1642-47. [CrossRef] google scholar
• 20. Tanida M, Mori M. Nesfatin-1 stimulates renal sympathetic nerve activity in rats. Neuroreport 2011;22(6):309-12. [CrossRef] google scholar
• 21. Başar Ö, Akbal E, Köklü S, Koçak E, Tuna Y, Ekiz F, et al. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest 2012;72(6):479-83. [CrossRef] google scholar
• 22. Ayyildiz T, Dolar E, Barbaros O, Arıkan Ş, Balaban S. Nonalcoholic Fatty Liver Disease and Its Association with Serum Nesfatin-1. Anatol Clin J Med Sci 2022;26(1):45-53. [CrossRef] google scholar